Moreover, drugs and biologics targeted at key molecules of these complex signaling pathways, such as RISP, ATM, and NF-κB, may become more effective and specific therapeutic options for treating PH in COPD and other devastating inflammatory lung diseases. The gene discussed is NFKB1; the disease is chronic obstructive pulmonary disease.